Jonathan joined Brandon Capital in 2021.
Jonathan is a Partner based in Brandon’s London office and serves on the boards of Pheon Therapeutics, Myricx Bio, AstronautX, Salvina, Catalym, and Cincera. Previously, he was a Managing Director at Arix Bioscience, where he built the team and portfolio, sitting on boards including Artios Pharma and VelosBio (acquired by Merck for $2.75bn). Before Arix, Jonathan was a Principal at Touchstone Innovations, helping build biotech spin-outs like Inivata (acquired for $415m).
Jonathan holds a first-class degree in Biology from Oxford University, a PhD in Molecular Medicine from UCL, and an MBA from Imperial College. He conducted postdoctoral research on cancer cell signalling at Cancer Research UK, publishing in Nature Genetics and NEJM. He is a trustee of the Autism Centre for Excellence, investor-in-residence at Cancer Research Horizons, and part of the KHAN drug discovery fund investment advisory committee.
